{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T23:02:54Z","timestamp":1778194974324,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Boehringer Ingelheim and Eli Lilly and Company."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The sodium\u2013glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04157751\">NCT04157751<\/jats:ext-link>), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10\u2009mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3\u2009days) and were treated for up to 90\u2009days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5\u2009point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90\u2009days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09\u20131.68; <jats:italic>P<\/jats:italic>\u2009=\u20090.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90\u2009days after starting treatment.<\/jats:p>","DOI":"10.1038\/s41591-021-01659-1","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T17:03:04Z","timestamp":1646067784000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":784,"title":["The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-4415","authenticated-orcid":false,"given":"Adriaan A.","family":"Voors","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-7637","authenticated-orcid":false,"given":"Christiane E.","family":"Angermann","sequence":"additional","affiliation":[]},{"given":"John R.","family":"Teerlink","sequence":"additional","affiliation":[]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-9789","authenticated-orcid":false,"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Michael E.","family":"Nassif","sequence":"additional","affiliation":[]},{"given":"Mitchell A.","family":"Psotka","sequence":"additional","affiliation":[]},{"given":"Jasper","family":"Tromp","sequence":"additional","affiliation":[]},{"given":"C. Jan Willem","family":"Borleffs","sequence":"additional","affiliation":[]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[]},{"given":"Joseph","family":"Comin-Colet","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Fu","sequence":"additional","affiliation":[]},{"given":"Stefan P.","family":"Janssens","sequence":"additional","affiliation":[]},{"given":"Robert G.","family":"Kiss","sequence":"additional","affiliation":[]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9348-3149","authenticated-orcid":false,"given":"Henrik","family":"Schirmer","sequence":"additional","affiliation":[]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[]},{"given":"Lenka","family":"Spinarova","sequence":"additional","affiliation":[]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6335-0273","authenticated-orcid":false,"given":"Jerzy K.","family":"Wranicz","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[]},{"given":"Shelley","family":"Zieroth","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-0746","authenticated-orcid":false,"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9354-9657","authenticated-orcid":false,"given":"Jonathan P.","family":"Blatchford","sequence":"additional","affiliation":[]},{"given":"Afshin","family":"Salsali","sequence":"additional","affiliation":[]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"1659_CR1","unstructured":"Writing Group Members, Mozaffarian, D. et al. Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association. Circulation 133, e38\u2013360 (2016)."},{"key":"1659_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD Causes of Death Collaborators","year":"2018","unstructured":"GBD Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1736\u20131788 (2018).","journal-title":"Lancet"},{"key":"1659_CR3","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","volume":"8","author":"J Tromp","year":"2020","unstructured":"Tromp, J. et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob. Health 8, e411\u2013e422 (2020).","journal-title":"Lancet Glob. Health"},{"key":"1659_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","volume":"381","author":"M Metra","year":"2019","unstructured":"Metra, M. et al. Effects of serelaxin in patients with acute heart failure. N. Engl. J. Med. 381, 716\u2013726 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR5","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","volume":"363","author":"BM Massie","year":"2010","unstructured":"Massie, B. M. et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 363, 1419\u20131428 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam, M. A. et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297, 1319\u20131331 (2007).","journal-title":"JAMA"},{"key":"1659_CR7","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"M Packer","year":"2017","unstructured":"Packer, M. et al. Effect of ularitide on cardiovascular mortality in acute heart failure. N. Engl. J. Med. 376, 1956\u20131964 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR8","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2019.18598","volume":"322","author":"N Kozhuharov","year":"2019","unstructured":"Kozhuharov, N. et al. Effect of a strategy of comprehensive vasodilation vs usual care on mortality and heart failure rehospitalization among patients with acute heart failure: the GALACTIC randomized clinical trial. JAMA 322, 2292\u20132302 (2019).","journal-title":"JAMA"},{"key":"1659_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med. 384, 117\u2013128 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/ejhf.1713","volume":"22","author":"K Damman","year":"2020","unstructured":"Damman, K. et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur. J. Heart Fail. 22, 713\u2013722 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1659_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad, F. et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396, 819\u2013829 (2020).","journal-title":"Lancet"},{"key":"1659_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","volume":"12","author":"SJ Greene","year":"2015","unstructured":"Greene, S. J. et al. The vulnerable phase after hospitalization for heart failure. Nat. Rev. Cardiol. 12, 220\u2013229 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"1659_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez, E. J. et al. Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure. N. Engl. J. Med. 380, 539\u2013548 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJM199209033271002","volume":"327","author":"K Swedberg","year":"1992","unstructured":"Swedberg, K. et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 327, 678\u2013684 (1992).","journal-title":"N. Engl. J. Med."},{"key":"1659_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ejhf.2137","volume":"23","author":"J Tromp","year":"2021","unstructured":"Tromp, J. et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur. J. Heart Fail. 23, 826\u2013834 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"1659_CR19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/10543406.2017.1397007","volume":"28","author":"G Dong","year":"2018","unstructured":"Dong, G., Qiu, J., Wang, D. & Vandemeulebroecke, M. The stratified win ratio. J. Biopharm. Stat. 28, 778\u2013796 (2018).","journal-title":"J. Biopharm. Stat."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01659-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01659-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01659-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:32:52Z","timestamp":1647880372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01659-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1659"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01659-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"29 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A.V. has received research support and\/or has been a consultant for Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novo Nordisk, Novartis, and Roche Diagnostics. C.E.A. has received research\/grant support and\/or has been a consultant for Abbott, Boehringer Ingelheim, Medtronic, Novartis, ResMed, Thermo Fisher, Vifor and German Federal Ministry of Education and Research. J.R.T. has received research support and\/or has been a consultant for Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Medtronic, Merck, Novartis, Servier, and Windtree Therapeutics. S.P.C. is a consultant for Aiphia, Siemens, Bristol Myers Squibb, Boehringer Ingelheim and Vixiar and receives research support from the NIH, PCORI, AstraZeneca and Beckman Coulter. M.K. has received research grants from AstraZeneca and Boehringer Ingelheim, and has served as a consultant for AstraZeneca, Amgen, Applied Therapeutics, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion Therapeutics, Janssen, Merck (Diabetes and Cardiovascular), Novo Nordisk, Sanofi and Vifor. J.P.F. is a consultant for Boehringer Ingelheim and receives research support from AstraZeneca. M.E.N. has received speaking honoraria from Abbott, and is a consultant for Vifor, Roche and Amgen. J.T. is supported by the National University of Singapore Start-Up grant and has been a consultant and holds minor stocks for Us2.ai, and has received personal fees from Roche Diagnostics, Daiichi Sankyo, Boehringer Ingelheim and has a patent awarded for an \u2018Automatic clinical workflow\u2019 that recognizes and analyzes 2D and Doppler modality echocardiogram images for automated cardiac measurements. C.J.W.B. has received personal fees from AstraZeneca, Boehringer Ingelheim and Novartis. C.M. has received personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Johnson & Johnson and Pfizer. J.C.-C. has received unrestricted grants from Vifor and Novartis paid directly to his institute, and consulting fees from AstraZeneca, Bayer, and Boehringer Ingelheim. M.F. has received research grants from AstraZeneca, Novartis and Vifor Pharma; and fees as a speaker or consultant for AstraZeneca, Bayer AG, Boehringer Ingelheim, Novo Nordisk, Novartis and Pharmacosmos. R.J.M. reports research support and personal fees from Boehringer Ingelheim, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Medtronic, Merck, Novartis, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. Y.S. reports consulting fees and honoraria from Boehringer Ingelheim. H.S. has received unrestricted grants from AstraZeneca paid directly to his institute, and consulting fees from Novartis and speaking fees from MSD, Pfizer, Sanofi and Amgen. M.S. has received personal payments from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Novartis. P.C.S. received honoraria and travel support from Bayer, AstraZeneca, Daiichi Sankyo, Novartis, Actelion, Roche, Sanofi Aventis, Pharmacosmos, Medtronic, Thoratec, Boehringer Ingelheim, Heartware, Coronus, Abbott, Edwards Inc., Boston Scientific, St. Jude Medical, Abiomed, and the German Cardiac Society. P.C.S. also received research support from the National Institute of Health (USA), the German Research Foundation, the Else Kr\u00f6ner Fresenius Foundation, German Heart Foundation, the European Society of Cardiology, Actelion, Medtronic, BMBF, Abiomed, Boehringer Ingelheim and Boston Scientific. P.C.S. served on advisory boards for the German Research Council, Eurotransplant, Novartis, Bayer, Pharmacosmos, AstraZeneca, Boehringer Ingelheim, the German Cardiac Society and the European Society of Cardiology. U.Z. received personal payments from AstraZeneca, Boehringer Ingelheim and Novartis. S.Z. has received consulting and or personal fees from Abbott, Akcea, AstraZeneca, Amgen, Alnylam, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Janssen, Merck, Novartis, Novo Nordisk, Otsuka, Pfizer, Servier and Vifor. M.B. and A.S. are employees of Boehringer Ingelheim. J.P.B. is an employee of Elderbrook Solutions GmbH. P.P. reports personal fees from Boehringer Ingelheim, AstraZeneca, Servier, Bristol Myers Squibb, Amgen, Novartis, Merck, Pfizer, Berlin Chemie, and grants and personal fees from Vifor Pharma. J.B., M.A.P., S.P.J., R.G.K., L.S., M.V. and J.K.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}